The effect of P-CAB in patients with functional dyspepsia; A prospective, single-arm, multicenter study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0005600

Enrollment

187

Registered

2020-11-13

Start date

2020-11-11

Completion date

Unknown

Last updated

2020-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Subjects who meet the exclusion criteria for selection of test results take 1 tablets once a day for 8 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? = 19 years ? Patients with functional dyspepsia that meet Roman criteria IV

Exclusion criteria

Exclusion criteria: ? In case of esophagus stenosis, ulcer stenosis, esophageal varix, Barrett's esophagus, active peptic ulcer, GI bleeding and Eosinophilic esophagitis on upper gastrointestinal endoscopy ? Patients who have undergone surgery on the esophagus, stomach, and duodenum ? Patients with a history of malignant tumors within the last 5 years ? Patients with clinically significant disorders in liver, kidney, cardiovascular system, respiratory system, endocrine system, and central nervous system ? Those who have a history of hypersensitivity reactions to components of tegoprazan or benzimidazoles ? Those who are administering atazanavir, nelpinavir, or drug containing rilpivirine ? pregnant or lactating women ? Any other condition likely in the judgment of the investigator that make the participants unable to complete, or is unsuitable for the study.

Design outcomes

Primary

Measure	Time frame
Overall Responder rate	—

Secondary

Measure	Time frame
Overall improvement in dyspepsia symptoms	—

Countries

Korea, Republic of

Contacts

Public ContactYoung Hoon Youn

Yonsei University Health System, Gangnam Severance Hospital

Outcome results